Moricizine

Moricizine

SCHEMBL16794

CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Moricizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 1.00
NR1I2 O75469 1/20 1.00
HTR1A P08908 1/20 1.00
CHRM1 P11229 1/20 1.00
PDE4D Q08499 1/20 1.00
KCNH2 Q12809 1/20 1.00
HIF1A Q16665 1/20 1.00
LMNA P02545 7/20 0.98
MEN1 O00255 3/20 0.98
KMT2A Q03164 3/20 0.98
GAA P10253 2/20 0.98
MAPK1 P28482 2/20 0.98
SMN1; SMN2 Q16637 1/20 0.98
CYP2C19 P33261 1/20 0.82
NR1I3 Q14994 4/20 0.73
MAPT P10636 5/20 0.70
TP53 P04637 2/20 0.70
HTT P42858 2/20 0.70
HSD17B10 Q99714 1/20 0.69
USP2 O75604 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Moricizine SCHEMBL29599149 1.00 CYP3A4 (1.00) CYP3A4NR1I2HTR1ACHRM1PDE4D
Moricizine SCHEMBL41358 0.99 LMNA (1.00) CYP3A4NR1I2HTR1ACHRM1PDE4D
Moricizine SCHEMBL41359 0.99 LMNA (1.00) CYP3A4NR1I2HTR1ACHRM1PDE4D
Moricizine SCHEMBL9447065 0.98 LMNA (0.98) CYP3A4NR1I2HTR1ACHRM1PDE4D
Moricizine SCHEMBL1650461 0.98 CYP3A4 (0.97) CYP3A4NR1I2HTR1ACHRM1PDE4D
SCHEMBL15913933 0.89 CYP3A4 (0.80) CYP3A4NR1I2HTR1ACHRM1PDE4D
Moricizine SCHEMBL2430390 0.88 CYP3A4 (0.78) CYP3A4NR1I2HTR1ACHRM1PDE4D
SCHEMBL19225040 0.85 NR1I3 (1.00) CYP3A4NR1I2HTR1ACHRM1PDE4D
SCHEMBL9446980 0.84 LMNA (0.72) CYP3A4NR1I2HTR1ACHRM1PDE4D
Moricizine SCHEMBL28086262 0.84 CYP3A4 (0.70) CYP3A4NR1I2HTR1ACHRM1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4063 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12117453-B2 Predicting patient response to sodium channel blockers WASHINGTON UNIVERSITY (US) 2024-10-15 US claimed
EP-3863708-B1 MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING BATTELLE MEMORIAL INSTITUTE (US) 2024-09-11 EP claimed
EP-4176841-A1 PROSTHETIC TISSUE VALVES Cormatrix Cardiovascular, Inc. (US) 2023-05-10 EP claimed
US-11642419-B2 Compositions and methods for treating cardiovascular related disorders THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-05-09 US claimed
EP-2991588-B1 PROSTHETIC TISSUE VALVES CORMATRIX CARDIOVASCULAR INC (US) 2022-10-12 EP claimed
EP-3618813-B1 IMPROVED EXTENDED RELEASE HIGHLY LOADED DRUG COMPOSITIONS LUBRIZOL ADVANCED MAT INC (US) 2022-07-06 EP claimed
US-11318107-B2 Pharmaceutical active-containing film delivery device for oral transmucosal administration Avior, Inc. (US) 2022-05-03 US claimed
US-20210085622-A1 TRANSMUCOSAL FILM COMPOSITION AND METHODS OF MAKING AND USING THE SAME Avior, Inc. 2021-03-25 US claimed
US-20210030693-A1 PHARMACEUTICAL ACTIVE-CONTAINING FILM DELIVERY DEVICE FOR ORAL TRANSMUCOSAL ADMINISTRATION Avior, Inc. 2021-02-04 US claimed
EP-3768378-A2 A NOVEL METHOD TO SLOW VENTRICULAR RATE InCarda Therapeutics, Inc. (US) 2021-01-27 EP claimed
US-6369114-B1 Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation INSTITUTE OF CRITICAL CARE MEDICINE 2002-04-09 US claimed
EP-1183011-A1 METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO Esperion Mergerco, Inc. (US) 2002-03-06 EP claimed
WO-2001092283-A2 COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-12-06 WO claimed
WO-2001079554-A1 GENETIC DIAGNOSIS FOR QT PROLONGATION RELATED ADVERSE DRUG REACTIONS GEORGETOWN UNIVERSITY (US) 2001-10-25 WO claimed
WO-2001039761-A1 ADMINISTRATION OF AN ALPHA-2 ADRENERGIC RECEPTOR AGONIST TO ENHANCE CARDIOPULMONARY RESUSCITATION INSTITUTE OF CRITICAL CARE MEDICINE (US) 2001-06-07 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000069412-A1 METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO ESPERION LUV DEVELOPMENT, INC. (US) 2000-11-23 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-1993010108-A1 PROCESS FOR THE PREPARATION OF MORICIZINE HYDROCHLORIDE THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-05-27 WO claimed
US-5202435-A Reacting ethanol solution of moricizine with hydrochloric acid at specified molar ratio DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-04-13 US claimed